EA200970515A1 - МОДИФИЦИРОВАННЫЕ РАСТВОРИМЫЕ СЛИТЫЕ КОНСТРУКЦИИ РЕЦЕПТОРА FGF И Fc С УЛУЧШЕННОЙ БИОЛОГИЧЕСКОЙ АКТИВНОСТЬЮ - Google Patents

МОДИФИЦИРОВАННЫЕ РАСТВОРИМЫЕ СЛИТЫЕ КОНСТРУКЦИИ РЕЦЕПТОРА FGF И Fc С УЛУЧШЕННОЙ БИОЛОГИЧЕСКОЙ АКТИВНОСТЬЮ

Info

Publication number
EA200970515A1
EA200970515A1 EA200970515A EA200970515A EA200970515A1 EA 200970515 A1 EA200970515 A1 EA 200970515A1 EA 200970515 A EA200970515 A EA 200970515A EA 200970515 A EA200970515 A EA 200970515A EA 200970515 A1 EA200970515 A1 EA 200970515A1
Authority
EA
Eurasian Patent Office
Prior art keywords
receptor
fgf
biological activity
modified soluble
designs
Prior art date
Application number
EA200970515A
Other languages
English (en)
Other versions
EA018700B1 (ru
Inventor
Марк Несбит
Беатрис Камерон
Франсис БЛАНШ
Сильви Сорделло
Селин Николацци
Марк Тромб
Original Assignee
Сентелион
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39431092&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200970515(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сентелион filed Critical Сентелион
Publication of EA200970515A1 publication Critical patent/EA200970515A1/ru
Publication of EA018700B1 publication Critical patent/EA018700B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Abstract

Изобретение относится к модифицированным растворимым слитым конструкциям рецептора FGF и Fc, содержащим слияние растворимого фрагмента или домена части рецептора FGF (нацеливающий или связывающий компонент) с Fc-областью части иммуноглобулина (компонент с эффекторной функцией), обладающим улучшенной биологической активностью, включая активности в отношении ADCC/CDC, содержащим их композициям и способу получения таких модифицированных растворимых слитых молекул рецептора FGF и Fc.
EA200970515A 2006-11-28 2007-11-28 МОДИФИЦИРОВАННЫЕ РАСТВОРИМЫЕ СЛИТЫЕ КОНСТРУКЦИИ РЕЦЕПТОРА FGF И Fc С УЛУЧШЕННОЙ БИОЛОГИЧЕСКОЙ АКТИВНОСТЬЮ И ИХ ПРИМЕНЕНИЕ EA018700B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06291824 2006-11-28
EP07290042 2007-01-11
PCT/IB2007/004354 WO2008065543A2 (en) 2006-11-28 2007-11-28 Modified soluble fgf receptor fc fusions with improved biological activity

Publications (2)

Publication Number Publication Date
EA200970515A1 true EA200970515A1 (ru) 2009-12-30
EA018700B1 EA018700B1 (ru) 2013-10-30

Family

ID=39431092

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970515A EA018700B1 (ru) 2006-11-28 2007-11-28 МОДИФИЦИРОВАННЫЕ РАСТВОРИМЫЕ СЛИТЫЕ КОНСТРУКЦИИ РЕЦЕПТОРА FGF И Fc С УЛУЧШЕННОЙ БИОЛОГИЧЕСКОЙ АКТИВНОСТЬЮ И ИХ ПРИМЕНЕНИЕ

Country Status (33)

Country Link
US (3) US8119770B2 (ru)
EP (1) EP2092069B2 (ru)
JP (1) JP2010510801A (ru)
KR (1) KR20090102769A (ru)
AR (1) AR063975A1 (ru)
AT (1) ATE509106T1 (ru)
AU (1) AU2007326985C1 (ru)
BR (1) BRPI0719290A2 (ru)
CA (1) CA2668932A1 (ru)
CL (1) CL2007003411A1 (ru)
CO (1) CO6190564A2 (ru)
CR (1) CR10777A (ru)
CY (1) CY1112435T1 (ru)
DK (1) DK2092069T3 (ru)
EA (1) EA018700B1 (ru)
EC (1) ECSP099361A (ru)
GT (1) GT200900137A (ru)
HR (1) HRP20110503T1 (ru)
IL (1) IL198480A0 (ru)
MA (1) MA31143B1 (ru)
MX (1) MX2009005692A (ru)
MY (1) MY145914A (ru)
NI (1) NI200900097A (ru)
NO (1) NO20092414L (ru)
PE (1) PE20081250A1 (ru)
PL (1) PL2092069T3 (ru)
PT (1) PT2092069E (ru)
RS (1) RS51911B (ru)
SI (1) SI2092069T1 (ru)
SV (1) SV2009003272A (ru)
TN (1) TN2009000184A1 (ru)
TW (1) TW200839012A (ru)
WO (1) WO2008065543A2 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2560589C2 (ru) * 2011-05-20 2015-08-20 Яньтай Жунчан Байотекнолоджиз Ко., Лтд. Слитный белок антиангиогенного индуцирующего фактора и его применение

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2520654B8 (en) 2003-08-26 2017-04-19 The Regents of the University of Colorado, a body corporate Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
WO2007014123A2 (en) 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
EP2318529B1 (en) 2008-08-04 2017-10-18 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
ES2600631T3 (es) * 2009-11-13 2017-02-10 Five Prime Therapeutics, Inc. Uso de proteínas del dominio extracelular de FGFR1 para tratar cánceres caracterizados por mutaciones activadoras dependientes de ligando en FGFR2
US8685931B2 (en) 2009-12-17 2014-04-01 Five Prime Therapeutics, Inc. Hair growth methods using FGFR3 extracellular domains
FR2958936A1 (fr) 2010-04-14 2011-10-21 Sanofi Aventis Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
AU2015258172B2 (en) * 2010-11-15 2017-01-12 Five Prime Therapeutics, Inc. Fgfr1 extracellular domain combination therapies
AU2011329127B2 (en) 2010-11-15 2015-09-03 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) * 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
MA34827B1 (fr) 2010-12-23 2014-01-02 Sanofi Sa Protéine hybrides robo1-fc à utiliser dans traitement d'hépatocarcinomes
AR085302A1 (es) * 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
EP2723370A4 (en) 2011-06-24 2015-06-03 Univ Colorado Regents COMPOSITIONS, PROCESS AND USE OF ALPHA-1-ANTITRYPHIN FUSION MOLECULES
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
CA2855818A1 (en) 2011-11-14 2013-05-23 Five Prime Therapeutics, Inc. A method of treating lung cancer having an fgfr1 gene amplification or fgfr1 overexpression
KR102348985B1 (ko) 2012-01-10 2022-01-12 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
US20150344855A1 (en) 2013-01-16 2015-12-03 INSERM (Institut National de la Santé et de la Recherche Médicale A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders
US9925240B2 (en) 2013-03-06 2018-03-27 Genentech, Inc. Methods of treating and preventing cancer drug resistance
BR112015020885A2 (pt) * 2013-03-11 2017-10-10 Genzyme Corp polipeptídeos de ligação hiperglicosilados
US9957313B2 (en) 2013-03-15 2018-05-01 Remegen, Ltd. FGFR-FC fusion proteins and the use thereof
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
AU2014268519A1 (en) * 2013-05-23 2015-11-05 Five Prime Therapeutics, Inc. Methods of treating cancer
NZ715201A (en) 2013-08-01 2021-12-24 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
EP3129067B1 (en) 2014-03-19 2023-01-04 Genzyme Corporation Site-specific glycoengineering of targeting moieties
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
BR112018010410A8 (pt) * 2015-11-23 2019-02-26 Five Prime Therapeutics Inc método para tratar câncer em um sujeito, composição e métodos de aumento do número de células nk e de aumento do número de uma ou mais células positivas para pd-l1
BR112019023898A2 (pt) 2017-05-16 2020-06-09 Five Prime Therapeutics Inc método para tratamento de câncer gástrico, uso de um anticorpo e composição
WO2019106592A2 (en) 2017-11-30 2019-06-06 Grifols Diagnostic Solutions Inc. Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors pd1 and pd-l1
CR20200327A (es) * 2018-01-26 2020-11-05 Genentech Inc Proteínas de fusión fc il-22 y métodos de uso

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288856A (en) 1986-11-20 1994-02-22 Pierre Amiguet Method of isolating acid-stable, biologically active proteins
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5750375A (en) * 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5288855A (en) * 1989-01-23 1994-02-22 Farmitalia Carlo Erba Extracellular form of the human fibroblast growth factor receptor
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5153310A (en) * 1989-02-28 1992-10-06 Du Pont Merck Pharmaceutical Company Il-2 analogs containing n-linked glycosylation sites
WO1991000916A2 (en) 1989-07-06 1991-01-24 The Regents Of The University Of California Receptors for fibroblast growth factors
EP0529076B1 (en) * 1990-04-27 1995-12-06 Takeda Chemical Industries, Ltd. Proteins with fibroblast growth factor receptor activity
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
DE69133281T2 (de) 1990-07-06 2004-05-06 Gencell S.A. Rezeptoren der wachstumsfaktoren aus fibroblasten
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US20020045207A1 (en) * 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
AU3224700A (en) * 1999-02-08 2000-08-25 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US6612152B2 (en) * 1999-05-01 2003-09-02 James E. Keaton Lifting, servicing, and diagnosing automobiles
US6656738B1 (en) * 1999-11-17 2003-12-02 Bae Systems Integrated Defense Solutions Inc. Internal heater for preconcentrator
CA2412882A1 (en) * 2000-06-30 2002-01-10 Maxygen Aps Peptide extended glycosylated polypeptides
CA2785941C (en) 2000-10-06 2017-01-10 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2003074679A2 (en) * 2002-03-01 2003-09-12 Xencor Antibody optimization
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
DK2345671T3 (en) * 2002-09-27 2016-02-15 Xencor Inc Optimized Fc variants and methods for their formation
US20050239088A1 (en) 2003-05-16 2005-10-27 Shepard H M Intron fusion proteins, and methods of identifying and using same
CA2542130A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Cell genomically modified to produce polypeptides with an altered glycosylation pattern
DE102004022895A1 (de) 2004-05-10 2005-12-08 Adam Opel Ag Schallabsorbierendes Verkleidungselement
EP2471813B1 (en) 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
US20060223147A1 (en) * 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
US20060234347A1 (en) 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
EP1746161A1 (en) * 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
WO2007014123A2 (en) * 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
EP1931709B1 (en) 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2560589C2 (ru) * 2011-05-20 2015-08-20 Яньтай Жунчан Байотекнолоджиз Ко., Лтд. Слитный белок антиангиогенного индуцирующего фактора и его применение

Also Published As

Publication number Publication date
EP2092069A2 (en) 2009-08-26
US8481487B2 (en) 2013-07-09
CY1112435T1 (el) 2015-12-09
MX2009005692A (es) 2009-10-12
KR20090102769A (ko) 2009-09-30
TW200839012A (en) 2008-10-01
SI2092069T1 (sl) 2011-09-30
MY145914A (en) 2012-05-15
AR063975A1 (es) 2009-03-04
BRPI0719290A2 (pt) 2014-02-25
AU2007326985B2 (en) 2013-08-15
PE20081250A1 (es) 2008-10-07
AU2007326985C1 (en) 2014-02-20
ECSP099361A (es) 2009-06-30
EP2092069B1 (en) 2011-05-11
US20100061979A1 (en) 2010-03-11
WO2008065543A3 (en) 2008-08-14
CO6190564A2 (es) 2010-08-19
EP2092069B2 (en) 2013-12-18
JP2010510801A (ja) 2010-04-08
DK2092069T3 (da) 2011-08-29
PT2092069E (pt) 2011-07-29
HRP20110503T1 (hr) 2011-08-31
SV2009003272A (es) 2010-02-05
MA31143B1 (fr) 2010-02-01
CL2007003411A1 (es) 2008-07-04
EA018700B1 (ru) 2013-10-30
NO20092414L (no) 2009-08-21
WO2008065543A2 (en) 2008-06-05
GT200900137A (es) 2011-09-02
RS51911B (en) 2012-02-29
TN2009000184A1 (en) 2010-10-18
US20140030265A1 (en) 2014-01-30
IL198480A0 (en) 2011-08-01
US8119770B2 (en) 2012-02-21
CR10777A (es) 2009-07-23
AU2007326985A1 (en) 2008-06-05
NI200900097A (es) 2010-01-26
US20120195851A1 (en) 2012-08-02
PL2092069T3 (pl) 2011-10-31
ATE509106T1 (de) 2011-05-15
CA2668932A1 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
EA200970515A1 (ru) МОДИФИЦИРОВАННЫЕ РАСТВОРИМЫЕ СЛИТЫЕ КОНСТРУКЦИИ РЕЦЕПТОРА FGF И Fc С УЛУЧШЕННОЙ БИОЛОГИЧЕСКОЙ АКТИВНОСТЬЮ
CY1123752T1 (el) Πρωτεϊνες δεσμευσης ιντερλευκινης-13
EA201390923A1 (ru) Модифицированное антитело с улучшенным полупериодом существования
ATE455127T1 (de) Humane anti-humane cd3-bindungsmoleküle
NO20092285L (no) Humane, monoklonale antistoffer til BTLA og fremgangsmater for anvendelse
WO2011091078A3 (en) Antibody fc variants with enhanced complement activity
WO2008147143A3 (en) Immunoglobulin fusion proteins
WO2006116260A3 (en) Modulation of antibody effector function by hinge domain engineering
EP2352523A4 (en) IMPROVED ANTI-CD19 ANTIBODIES
EP2511301A3 (en) Human antibodies to ERBB2
NZ591471A (en) Antibodies to ccr2
WO2009112245A9 (en) Antibody against the csf-1 r
AU2018272852A8 (en) Antibodies comprising modified heavy constant regions
MX2009007290A (es) Compuestos agonistas del receptor de la proteina 1 similar al glucagon.
MX2012003939A (es) Fusiones y conjugados de farmaco.
DK1951759T3 (da) Anti-EGFR-antistoffer
WO2008070344A3 (en) Compositions and methods for binding sphingosine-1-phosphate
WO2009081285A3 (en) Hepatitis c virus antibodies
EA201100923A1 (ru) Антитела человека против тканевого фактора
PE20120415A1 (es) Anticuerpos anti-igf
WO2009071696A3 (en) Humanized antibody molecules specific for il-31
WO2008079995A3 (en) Conjugate of natriuretic peptide and antibody constant region
WO2008091798A3 (en) Optimized ca9 antibodies and methods of using the same
CO6260104A2 (es) Anticuerpos contra la il-25
WO2008048519A3 (en) Antibodies that bind cxcr7 epitopes

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU